In the China group:
The most common adverse reaction in the China group was low levels of red
blood cells. The table below shows the adverse reactions that happened in more
than 15.0% of participants in at least 1 treatment group during the study. There
were other adverse reactions, but these happened in fewer participants.
Most common adverse reactions in the China group
Durvalumab with Standard
tremelimumab treatment
(out of 77 (out of 78
Adverse reaction participants) participants)
Low levels of red blood cells 3.9% (3) 60.3% (47)
Reduced levels of neutrophils 3.9% (3) 44.9% (35)
Reduced levels of white blood cells 1.3% (1) 44.9% (35)
Nausea 2.6% (2) 42.3% (33)
Reduced levels of platelets, a type of
1.3% (1) 21.8% (17)
blood cell that can help form clots
Vomiting 2.6% (2) 24.4% (19)
Increased levels of alanine
aminotransferase, a sign of possible 22.1% (17) 24.4% (19)
liver damage
Increased levels of amylase, a protein
23.4% (18) 2.6% (2)
the body makes
Increased levels of aspartate
aminotransferase, a sign of possible 23.4% (18) 21.8% (17)
liver damage
Reduced appetite 7.8% (6) 19.2% (15)
Increased levels of lipase, a protein the
16.9% (13) 1.3% (1)
body makes
Low levels of white blood cells none 15.4% (12)
Weakness or lack of energy 6.5% (5) 15.4% (12)
18 | Clinical Study Results